11th Feb 2025 A plain language summary of the EV-302/KEYNOTE-A39 study: evaluating the effectiveness and safety of enfortumab vedotin (EV) with pembrolizumab in advanced urothelial cancer
18th Jan 2024 Plain language summary: looking at the enfortumab vedotin plus pembrolizumab treatment combination for untreated locally advanced or metastatic urothelial cancer
12th Apr 2023 Plain Language Summary: the CheckMate 274 study, treatment of muscle-invasive urothelial cancer with nivolumab
